BPC-157 Oral Bioavailability: What We Know

BPC-157 oral bioavailability refers to the proportion of the drug administered orally that ultimately enters the blood flow in an unaltered form. In general, the oral bioavailability of peptides is approximately zero, mainly due to the inactivation of the peptide in the stomach. Although BPC-157 is an exception in overcoming the acid degradation, it still does not guarantee its absorption. Even being stable in gastric environment for over 24 hours, the bioavailability of BPC-157 was quantified to be low: 2-7% for rats and 3-5% for dogs. Also, currently there have been no studies looking at the pharmacokinetics of BPC-157 in humans.

Why Oral Bioavailability Matters

The Definition

When a drug is injected intravenously, 100% of the dose enters the bloodstream. That is the reference point. Bioavailability measures what percentage of an oral dose achieves the same systemic exposure. A drug with 50% oral bioavailability delivers half as much active compound to the blood as an equivalent IV dose. For peptides, this number is almost always below 2%, which is why insulin, growth hormone and nearly all therapeutic peptides are injected rather than swallowed.

Why Most Peptides Have Zero Oral Bioavailability

There are three major obstacles preventing the possibility of orally-administered peptides getting into the bloodstream. The first barrier results from gastric acid that immediately acts on most peptide formations, which has a pH of around 1-2. The second obstacle is represented by pepsin as well as pancreatic protease, which continue splitting peptide links in the stomach and small intestine. Finally, there is a problem with the absorption of peptides that were able to pass the gut. The intestinal epithelium is very restrictive about fat-soluble peptides, and so no substance over 500-700 daltons can be absorbed passively. However, BPC-157 at about 1419 daltons is well above that threshold.

BPC-157's Acid Stability: The First Exception

Gastric Acid Resistance

BPC-157 was originally isolated from human gastric juice, an environment of pH 1 to 2. The peptide evolved, in a sense, to exist in acid. Sikiric et al., 2011 documented that BPC-157 remained structurally intact at pH 1 to 2 for more than 24 hours in laboratory conditions. This property is remarkable for a 15-amino-acid peptide. Most peptides of similar length degrade within minutes under the same conditions.

Structural Basis for Stability

The BPC-157 sequence (GEPPPGKPADDAGLV) contains 3 proline residues. Proline introduces rigid kinks in the peptide backbone that limit protease access. The high proportion of small, non-bulky amino acids (glycine, alanine) and the overall charge distribution may also contribute. However, the exact structural features responsible for acid stability have not been fully characterized. It remains an observed property rather than a fully explained one.

Measured Bioavailability in Animals

The 2022 Pharmacokinetic Study

The only published pharmacokinetic dataset for BPC-157 comes from a 2022 study conducted in rats and dogs. After oral administration, BPC-157 appeared in plasma, confirming that some fraction crosses the intestinal barrier. Oral bioavailability was approximately 2 to 7% in rats and 3 to 5% in dogs. For comparison, intramuscular injection yielded 14 to 19% bioavailability in rats and 45 to 51% in dogs. Time to peak plasma concentration after oral dosing was 30 to 60 minutes in rats.

What These Numbers Mean

When the oral bioavailability is 5%, it means that if someone consumes 1000 mcg of any drug, only about 50 mcg of that drug may reach the bloodstream. The 950 mcg will either be destroyed in the body or removed from it without being absorbed. For instance, approximately 25 mcg of that drug will be absorbed into the bloodstream after consuming a 500 mcg capsule, assuming that the absorption in a human body works that way as well. It is not possible to conclude from the given data whether the 25 mcg dose is sufficient for therapeutic effect in a 70 kg person or not.

The Arginate Salt Hypothesis

How Salt Form Might Affect Absorption

BPC-157 exists in two commercially relevant forms: the free acid and the arginate salt. The arginate salt pairs the peptide with L-arginine, which alters its solubility and dissolution characteristics. Some researchers and manufacturers have hypothesized that the arginate form may dissolve faster in intestinal fluid, potentially improving absorption. This hypothesis has not been tested in a controlled bioavailability comparison. No published study has measured oral bioavailability of the arginate salt versus the free acid form in any species.

Why It Matters for Capsules

Products in capsules may come in either form, but most do not call out which. If the arginate salt increases oral bioavailability at all, then capsules using the free acid form may underperform. On the other hand, if bioavailability is the same for both forms, this is moot for customers. The impact of salt form on the bioavailability of capsules will remain unknown until published comparative PK studies. For more information on the topic of salt form, check out BPC-157 arginate guide.

Why Human Bioavailability Data Is Missing

No Phase I PK Study

Phase I Pharmacokinetics study is designed to be the first step any drug should go through. In this phase, the drug is examined in terms of its absorption, distribution, metabolism and excretion in healthy people. Unlike all other drugs, BPC-157 has never experienced such a study. This is due to both regulatory and commercial reasons. BPC-157 is somewhat of a gray area as it is not an FDA approved drug. It can be sold as a research chemical or supplement, and there is no patent protection that would incentivize a pharmaceutical company to invest in costly clinical trials.

The Consequence for Consumers

Without human pharmacokinetic information, claims about how well the oral capsule works can only be speculated based on animal model studies. The half-life of BPC-157 in human plasma remains unknown. The volume of distribution is not known, either. We have no information about how human gastrointestinal enzymes compare to rat enzymes when it comes to the rate of degradation of the peptide. There is no data on the first-pass effect of the liver either. This matters because first-pass metabolism could further reduce what reaches systemic circulation. Half-life and volume of distribution are some of the most important pharmacokinetic parameters needed to determine whether a certain dose of the capsule will have any effect.

Local vs Systemic: A Critical Distinction

Gut-Targeted Use

Low systemic bioavailability may be less of a problem than it first appears, if the target is the gut itself. After oral dosing, BPC-157 achieves high local concentrations in the GI lumen before most of it is degraded or excreted. For gut mucosal protection, local concentration likely matters more than plasma levels. The gastric ulcer and fistula studies in rats support this idea: oral BPC-157 produced effects comparable to injection for gut-specific outcomes (Cesarec et al., 2013).

Systemic Targets

For targets outside the GI tract, such as tendons, muscles, joints or the nervous system, systemic bioavailability is the rate-limiting factor. The peptide must cross the intestinal wall, survive first-pass metabolism and reach distant tissue at a concentration high enough to trigger biological effects. With oral bioavailability of 2 to 7% in rats, this is a steep hill. The musculoskeletal injury studies that form the backbone of BPC-157's reputation almost exclusively used injection, not oral dosing. See our capsules vs injection comparison for a route-by-route breakdown.

Implications for Capsule Buyers

BPC-157 capsules deliver the peptide to the GI tract, where it is acid-stable and has demonstrated local protective effects in animal models. For systemic applications, the oral route delivers far less peptide to the bloodstream than injection. Whether capsule doses of 200 to 500 mcg produce pharmacologically relevant systemic concentrations in humans is simply not known. Real Peptides offers BPC-157 Capsules (100 count, 500 mcg each, $120) with HPLC-verified purity and lot-specific COA, which addresses the quality variable but not the bioavailability question.

Given these uncertainties around BPC-157 oral bioavailability, it is recommended that you talk to a qualified health and wellness professional before using capsules for any health-related reason. The lack of human pharmacokinetic data also means that none can be called clinically effective and that people's reactions to it may vary considerably. A qualified health professional can help determine whether pre-clinical evidence is applicable to your particular situation.